Project Grant R01AI179309
Award Date
7/10/24
Completion Date
6/30/29
Dollars Obligated
$762K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This $510,306 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to advance the understanding of virus-host interactions for developing a cure against chronic hepatitis B virus (HBV) infections. The primary goal is to investigate the mechanisms by which interferon-alpha treatment can lead to a functional cure for HBV, as well as explore the impact of HBV...
This $847,428 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to understand the mechanisms of hepatitis B virus (HBV) persistence and clearance in chronic hepatitis B patients, with a focus on evaluating intrahepatic cccDNA and integrated DNA. The primary awardee, Beth Israel Deaconess Medical Center, will conduct translational research to quantify cccDNA and integrated DNA levels,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded Emory University a $673,158 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a proteomics atlas of HIV/HBV co-infections for advancing HBV cure strategies. The project aims to use robust co-culture systems, CRISPR screens, and multi-omics approaches in primary human hepatocytes and CD4+ T cells to discover and validate host factors and antivirals against HIV/HBV...
This $814,790 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to uncover the immune mechanisms underlying hepatitis B virus (HBV) surface antigen clearance, which can lead to a clinical cure for chronic HBV infection. The principal investigators at the University of California, San Francisco (UCSF) will leverage mouse models and clinical samples from HBV patients to conduct a...
This Project Grant award for $862,440.00 was made by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports the development and evaluation of a new humanized mouse model to study gene editing therapies targeting chronic hepatitis B virus (HBV) infection. The key objectives are to: 1) Evaluate the anti-HBV efficacy of HBV gene therapy in liver-humanized NSG-PIZ mice, including assessing...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $598,764 to The Trustees of Princeton University to conduct research aimed at disrupting the formation of HBV cccDNA to combat chronic HBV infection, particularly in the context of HIV co-infection. The key objectives are to: 1) determine whether genetic disruption of host factors involved in HBV cccDNA...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $162,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Pontificia Universidad Javeriana in Colombia. The grant supports research to evaluate the impact of reprogramming HBV-specific CD8+ T cells from individuals with chronic Hepatitis B infection, with the goal of enhancing their antiviral functions and therapeutic potential. The research aims to compare the functional...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $483,194 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Research Institute at Nationwide Children's Hospital. The grant, with a project period from March 2025 to February 2030, aims to define the protective CD4+ T cell response that supports effective CD8+ T cell immunity against the Hepatitis C Virus (HCV). The research will leverage historical blood and liver samples...
The University of Southern California received a $621,698 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to conduct research on mother-to-child transmission of hepatitis B virus (HBV). The goal is to understand how HBV and its antigens in the mother affect the anti-HBV immunity of her children, which can lead to chronic HBV infection. The research will identify maternal HBV factors that promote HBV...